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Down’s syndrome (DS, trisomy 21) results
from an extra copy of human chromosome 21.
Included in the phenotype of this syndrome is
the development of neurofibrillary tangles and
neuritic plaques that are characteristic of
Alzheimer’s disease (AD) (Wisniewski KE et al.,
Ann Neurol 1985; 17: 278-282). The hippo-
campus is an early and critical site of this
pathology. Animal models would greatly aid the
elucidation of processes underlying the
neuropathology of DS and AD. Murine trisomy
16 is a proposed genetic model for DS owing to
the homology between mouse chromosome 16
and human chromosome 21 (Epstein CJ, Trends
Genet 1985; 1: 129-134). To determine whether
the trisomy 16 mouse could be a useful model
for AD, we investigated whether trisomy 16
brain tissue develops AD neurodegeneration
and neuropathology. Because age is an impor-
tant factor in the development of AD neuro-
degeneration and trisomy 16 mice do not survive
past birth, neural tissue was maintained by
transplantation so that the neurons might live
long enough to express the AD phenotype. Tri-
somy 16 mice were produced by mating males
doubly heterozygous for the Robertsonian
translocations Rb(11.16)2H/Rb(16.17)32 Lub to
C57B1/6 females. Hippocampal anlagen from
embryonic day 15-17 fetal mice, trisomic for
chromosome 16 or euploid litter-mates, was
dissected free, cut into two or three pieces and
taken up into a 10 /zl Hamilton syringe. A
craniotomy was performed in host 6-8 week old
female C57B1/6 mice and the tissue was injected
stereotaxically into striatum or lateral ventricle.
In some cases, hippocampal tissue was dissoci-
ated with trypsin prior to grafting (Fine A,
Neurosci Lett 1991; 122: 4-8). Following up to
fourteen months of survival in vivo, brains were
fixed by perfusion with 4% paraformaldehyde,
sectioned and the grafts were examined by stan-
dard histochemical techniques and by immuno-
cytochemistry for senile plaques and neuro-
fibrillary tangles of AD patients. Nissl-stained
grafts appeared healthy with no areas of necrosis
or degeneration. The grafts contained neuronal
aggregates similar to the pyramidal- or the
granule-cell layers of the normal adult
hippocampus. No obvious morphological differ-
ence was detected between trisomic and control
transplants. No evidence of neuropathology was
found in thioflavin S- or silver-stained sections.
The monoclonal antibody Alz-50 (provided by
Dr. P. Davies, Albert Einstein College of
Medicine, and Dr. H. Ghanbari, Abbott Lab.),
which recognizes the paired helical filaments
characteristic of AD, did not stain trisomic or
euploid grafts. However, frontal cortex from an
AD patient, stained in parallel with the mouse
sections, reacted strongly, thus indicating that
the lack of staining in the mouse sections was not
a failure of the immunohistochemical procedure.
An antibody to/3-amyloid peptide (R1280, pro-
vided by Dr. I. Lieberberg, Athena Neuro-
sciences) revealed no/3-amyloid accumulation in
these grafts, whereas concurrent staining of AD
frontal cortex demonstrated numerous plaques.
We examined four trisomic en bloc grafts after
one year of survival, and two grafts each after
four, six and fourteen months using Alz-50 and
R1280 antibodies; none showed AD-type im-
munoreactivity. Four dissociated cell trisomic
grafts, after 18 months in vivo, did not stain with
Alz-50. Further, antibodies against ubiquitin, 200
kDa subunit of neurofilament and tau, which
stain neurofibrillary tangles, and antibodies
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against ctl-antichymotrypsin, which stains
plaques, demonstrated no AD-type pathology in
the trisomic or control grafts. In summary, we
found no evidence of neurodegeneration or AD-
type immunoreactivity in grafts of trisomic
hippocampal fragments in either the striatum or
the lateral ventricle. The present results stand in
contrast to the observation of neurofibrillary and
amyloid immunoreactivity in solid grafts of tri-
somy 16 fetal hippocampus after only 4 months
in vivo (Richards et al., EMBO J 1991; 10: 297-
303). While there are differences in grafting pro-
tocol and mouse strain between these two stud-
ies that may lead to variations in expression of
markers of cell pathology, it is clear that trisomy
16 tissue does not routinely develop any
neuropathology comparable to that found in
AD. In conclusion, we report that mouse trisomy
16 neurons maintained up to 18 months by
transplantation do not develop neuropathology
or AD-type immunoreactivity as seen in DS, and
thus do not provide a useful model for the
development of AD-type pathology.